Right. Clearly they are not going to stop improving DCVax-L until it can help all GBM patients to the maximum extent. No researcher worth their salt would say, "well look, we can help the lions share, so that's good enough."
Also, I want to take this opportunity to thank you again for explaining "double" rapid progressors way back when. Even though that subcategory is less talked about these days, because it is not as aesthetic on a chart, it is the data from the information arm that was most elucidating to me.
News 
Market Data 
Discover 
AI
